ORI-INDUSTRIES
4.10.2021 07:02:05 CEST | Business Wire | Press release
London based edge computing pioneer Ori Industries is partnering with VMware, Inc. (NYSE: VMW), a leading innovator in enterprise software, to facilitate enterprise implementation of edge computing across hybrid, telco and multi-cloud deployments. The interoperability of VMware Telco Cloud Platform and Ori Global Edge reduces complexity, increases service velocity, and manageability of cloud-native service delivery at the edge.
According to Gartner 1 , “edge computing is entering the mainstream”; however, many enterprises struggle with their existing cloud deployments proving to be a barrier to edge adoption. Ori and VMware’s partnership will help overcome this challenge by offering a fully functioning edge platform that connects to any cloud environment from telco to hybrid to multi-cloud.
Ori Global Edge on VMware Telco Cloud Platform is a managed cloud service offering that delivers a multi-connected edge by using multiple points of presence (PoP) that connect to the telco and communications service provider (CSP) infrastructure on one end and different clouds on the other end. The solution2 enables CSPs to offer multi-access edge computing (MEC) capabilities, which allow them to greater monetize their 5G offering to the enterprise. At the same time, it allows them to reduce their backhaul costs through intelligent workload placement.
Customers will benefit from service availability at the edge with low latency, highly-available applications generating and processing data locally without overhead for data transfer back to the cloud for processing. Extracting, analysing and using data at the edge permits a new class of enterprise services for enhanced customer experience.
Stephen Spellicy , vice president of product marketing, Service Provider and Edge, VMware, said, “Enterprises are looking for new ways to engage customers and deliver next-generation experiences. That means having the right application deployed where the user is. Edge computing is the final piece of the puzzle and working with Ori Industries’ multi-access edge computing platform will give mutual customers the ability to deploy a solution that helps cover all their environments – whether telco, hybrid, multi-cloud or edge – to meet their business needs.”
Douglas Mancini , CCO at Ori Industries said “Edge computing offers enterprises immense opportunities to not only deliver new innovative solutions but also reinvent their existing infrastructure in a more efficient way: Enterprises have learned that a pure cloud-first model has failed to deliver the expected value or agility, and Ori Global Edge is helping do just that. By combining our edge computing expertise with VMware Telco Cloud Platform and multi-cloud leadership, we are able to offer enterprises a way of harnessing the power of edge and reaping the benefits of being able to use data near to its creation.”3
For more information visit: https://ori.co/ .
About Ori Industries
Ori Industries is laying the foundation for the global rollout of edge computing services. The company’s edge platform simplifies workload provisioning across public, Telco, hybrid, and multi-cloud infrastructure to support countless new and emerging enterprise use cases. Ori Industries is based in London with a global workforce. For more information, please visit https://www.ori.co/ .
VMware and VMware Telco Cloud Platform are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
1
https://www.gartner.com/en/documents/3992656/2021-strategic-roadmap-for-edge-computing
2
Solution Overview: https://www.vmware.com/content/dam/digitalmarketing/vmware/en/pdf/microsites/telco/vmware-ori-solution-brief.pdf
3
Video Interview: https://www.youtube.com/watch?v=R-fUFNElWzo
View source version on businesswire.com: https://www.businesswire.com/news/home/20211003005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom